

Contents

Preface

v

1. Pilot Plant and Scale-up Techniques

1

- 1.1 Introduction 1
 - 1.1.1 Scale-up Process 1
 - 1.1.2 Significance of Pilot Plant Studies 2
 - 1.1.3 Steps involved in the Scale-up Process 2
 - 1.1.4 Pilot Plant Layout Design 2
 - 1.1.5 General Considerations of Pilot Plant 4
 - 1.1.6 GMP Consideration 11
 - 1.1.7 Product Considerations 11
- 1.2 Scale-up and Post-approval Changes 22
 - 1.2.1 Introduction 22
 - 1.2.2 Scientific and Regulatory Rationale for SUPAC 22
 - 1.2.3 Purposes of Guidelines 22
 - 1.2.4 SUPAC Guidelines 23
 - 1.2.5 Modern Regulatory Tools 30
 - 1.2.6 SUPAC Limitations 31
- 1.3 Postmarketing Surveillance 31
 - 1.3.1 Benefits of PMS System 31
 - 1.3.2 Importance of PMS 31
 - 1.3.3 PMS Sources of Information 32
 - 1.3.4 PMS Procedure 32
 - 1.3.5 Methods of Surveillance 32
 - 1.3.6 Modern Safety Surveillance and Real World Evidence 34
- 1.4 Platform Technology 34
 - 1.4.1 Introduction 34
 - 1.4.2 Key Benefits of a Well-established Platform Technology 35
 - 1.4.3 Designing Platform Technology 35
 - 1.4.4 Applications of Platform Technology 36
- 1.5 Recent Trends, Challenges and Future Directions in Pharmaceutical Regulation 37

2. Technology Transfer

40

- 2.1 Technology Transfer Protocol 40
 - 2.1.1 Reasons for Technology Process/Transfer 40
 - 2.1.2 Transfer Process 41
 - 2.1.3 Significance of Technology Transfer 42
 - 2.1.4 Confidentiality Agreement 43

- 2.2 Quality Risk Management 43
 - 2.2.1 QRM Principles 43
 - 2.2.2 Process of QRM 43
- 2.3 Transfer from R and D to Production 47
 - 2.3.1 Process Information 47
 - 2.3.2 Packaging 48
 - 2.3.3 Cleaning 48
- 2.4 Granularity of TT Process (Active Pharmaceutical Ingredient, Excipients, Finished Products and Packaging Materials) 48
 - 2.4.1 Active Pharmaceutical Ingredient 48
 - 2.4.2 Excipients 48
 - 2.4.3 Finished Products 49
 - 2.4.4 Packaging Materials 49
- 2.5 Documentation (Technology Transfer Dossier) 50
- 2.6 Premises and Equipment 51
 - 2.6.1 Premises 51
 - 2.6.2 Equipment 51
- 2.7 Qualification and Validation 52
 - 2.7.1 Qualification 53
 - 2.7.2 Validation 53
- 2.8 Quality Control: Analytical Method Transfer 54
- 2.9 Approved Regulatory Bodies and Agencies 54
- 2.10 Commercialization: Practical Aspects and Problems 57
 - 2.10.1 Practical Aspects 57
 - 2.10.2 Commercialization Problems 57
- 2.11 Case Studies 59
 - 2.11.1 Case Study 1: Scale-up of Drug–Excipient Mixing Process 59
 - 2.11.2 Case Study 2: Drug Layering on MCC Spheres 59

3. Regulatory Affairs

62

- 3.1 Introduction to Regulatory Affairs 62
 - 3.1.1 Regulatory Affairs 62
 - 3.1.2 Why Regulatory Affairs is needed? 62
 - 3.1.3 Historical Overview of Regulatory Affairs Globally 64
 - 3.1.4 Regulatory Authorities 66
 - 3.1.5 Role of Regulatory Affairs Personnels 69
 - 3.1.6 Responsibility of Regulatory Affair Professionals 70
 - 3.1.7 Global Harmonization in Regulatory Affairs 70
- 3.2 Regulatory Requirements for Drug Approval 71
 - 3.2.1 Drug Development Teams 71
 - 3.2.2 Non-clinical Drug Development Process 72
 - 3.2.3 General Considerations of Investigational New Drug Application 73

- 3.2.4 Investigator's Brochure 77
- 3.2.5 New Drug Application 80
- 3.2.6 Abbreviated New Drug Application 84
- 3.2.7 BA/BE Studies 90
- 3.2.8 Clinical Research Protocols 90
- 3.2.9 Biostatistics in Pharmaceutical Product Development 92
- 3.2.10 Management of Clinical Trials/Clinical Trial Management System (CTMS) 94
- 3.3 Regulatory Agencies 95
 - 3.3.1 India 95
 - 3.3.2 USA 97
 - 3.3.3 European Union 99
 - 3.3.4 Australia 101
 - 3.3.5 Japan 101
 - 3.3.6 Canada 104
- 3.4 Investigational Medicinal Product Dossier 105
 - 3.4.1 Objectives of IMPD 105
 - 3.4.2 Types of IMPD 105
 - 3.4.3 Contents of IMPD 106
- 3.5 Emerging Regulatory Trends 107

4. Quality Management Systems

109

- 4.1 Concept of Quality 109
 - 4.1.1 Types of Quality 109
 - 4.1.2 Dimensions of Quality 109
 - 4.1.3 Quality in the Era of Industry 4.0 and Industry 5.0 110
- 4.2 Total Quality Management 111
 - 4.2.1 Objectives of TQM 111
 - 4.2.2 Categories of TQM 112
 - 4.2.3 Principles of TQM 112
 - 4.2.4 Elements of TQM 113
- 4.3 Six Sigma Concept 115
 - 4.3.1 Objectives of Six Sigma 115
 - 4.3.2 Six Sigma Techniques 115
 - 4.3.3 Integration of Lean Six Sigma in Pharmaceuticals 117
- 4.4 Quality-by-Design 118
 - 4.4.1 Goals of QbD 119
 - 4.4.2 Flowchart of QbD 119
 - 4.4.3 Key Elements of QbD 119
 - 4.4.4 Difference between Current and QbD Approach 123
- 4.5 Out-of-Specification 123
 - 4.5.1 Out-of-Specification Investigation 123
 - 4.5.2 Out-of-trend Investigation 126

- 4.6 Change Control in Quality Management System 127
 - 4.6.1 Principles of Change Control 127
 - 4.6.2 Regulatory Requirements 127
 - 4.6.3 Change Control Steps 128
 - 4.6.4 Elements of Change Control 128
 - 4.6.5 Change Control under ICH Q10 and Q12 129
- 4.7 International Organization for Standardization 130
 - 4.7.1 Benefits of ISO Certification 130
 - 4.7.2 ISO Standards 130
- 4.8 ISO 9000 Series of Quality Management Systems Standards 130
 - 4.8.1 Benefits of Implementing ISO 9000 Quality Systems 131
 - 4.8.2 Key Elements of an ISO 9000 Quality Management System 131
 - 4.8.3 Quality Management Principles in ISO 9000:2015 and ISO 9001:2015 132
 - 4.8.4 ISO 9001:2015—Current Framework 133
- 4.9 ISO 9001:2008 133
 - 4.9.1 Steps to Implement ISO 9001:2008 Quality Management System 134
 - 4.9.2 Key Clauses of ISO 9001:2008 134
- 4.10 ISO 14000 136
 - 4.10.1 Aspects of ISO 14000 Environmental Management 136
 - 4.10.2 ISO 14000 Family Series 136
 - 4.10.3 Key Principles of the ISO 14000 Standards 137
 - 4.10.4 Benefits of ISO 14000 Certification 137
- 4.11 National Accreditation Board for Testing and Calibration Laboratories (NABL) 137
 - 4.11.1 Benefits of Accreditation 137
 - 4.11.2 Areas of Testing and Calibration Covered by NABL 138
 - 4.11.3 NABL Accreditation Process Flowchart 138
- 4.12 Good Laboratory Practice 140
 - 4.12.1 Objectives of GLP 140
 - 4.12.2 Principles of GLP 140
 - 4.12.3 Advantages 144
 - 4.12.4 Drawbacks 144
 - 4.12.5 Current Global Harmonization and the Shift to Digital GLP 144

5. Pharmaceutical Regulatory Agencies in India

147

- 5.1 Organization of Central Drugs Standard Control Organization (CDSCO) 147
 - 5.1.1 Drug Inspector (DI) 148
 - 5.1.2 Lower Division Clerk and Upper Division Clerk 148
 - 5.1.3 Multi-tasking Staff 149
- 5.2 Functions and Responsibilities of CDSCO 149
- 5.3 Preclinical Trial and Clinical Trials of CDSCO 150
 - 5.3.1 Regulation of Clinical Trials under NDCTR, 2019 150
- 5.4 Approval of Drugs through CDSCO 151

- 5.5 Regulatory Requirements for Product Approval 152
 - 5.5.1 Main Modules of CTD as per CDSCO 153
 - 5.5.2 Electronic Common Technical Document 153
- 5.6 Cosmetics and Medical Devices Approval as per CDSCO 154
 - 5.6.1 Approval of Cosmetics as per CDSCO 154
 - 5.6.2 Approval of Medical Devices as per CDSCO 155
- 5.7 Introduction to State Licensing Authority 155
 - 5.7.1 Organization of State Licensing Authority 156
- 5.8 Functions of SLA 157
- 5.9 Application Process for Site Registration and Manufacturing License 157
- 5.10 Certificate of Pharmaceutical Product 158
 - 5.10.1 General Requirements for Submission of CoPP 158
 - 5.10.2 Types of CoPP 158
 - 5.10.3 Process for Obtaining CoPP 158
 - 5.10.4 Format of CoPP 158

6. New Drug Discovery and Development**162**

- 6.1 Introduction to New Drug Discovery and Development 162
- 6.2 Stages of Drug Discovery and Development 162
 - 6.2.1 Pre-discovery 162
 - 6.2.2 Preclinical Research 165
 - 6.2.3 Clinical Trials 165
- 6.3 Concept of Generics 167
 - 6.3.1 Primary Requirement for Generic Medicines 168
 - 6.3.2 United States Food and Drug Administration (USFDA) Standards for a Generic Drug Product 168
 - 6.3.3 Innovator and Generic Products 168
- 6.4 Generic Product Development in Pharmaceutical Industries 169
 - 6.4.1 Strategies for Development 169
 - 6.4.2 Consideration of Patent Restrictions 169
 - 6.4.3 Selection and Characterization of Reference Products 169
 - 6.4.4 Target Market Selection 169
 - 6.4.5 Manufacturing Feasibility 170
- 6.5 Formulation Development 170
 - 6.5.1 Preformulation Study 170
 - 6.5.2 Selection of Excipient and Designing of Formulation Method 171
 - 6.5.3 Selection of Manufacturing Method 171
 - 6.5.4 Lead Formula Identification 171
 - 6.5.5 Analytical Method Development 171
 - 6.5.6 Site Transfer Batch or Submission Batches 172
 - 6.5.7 Stability Protocol 172
- 6.6 Abbreviated New Drug Application 172
 - 6.6.1 Types of Certifications 173

7. Registration of Indian Drug Products in Overseas Market	175
7.1 Procedure for Export of Pharmaceutical Products	175
7.1.1 Registration Process	175
7.1.2 Applications for an Export License	176
7.1.3 Certificate of Pharmaceutical Product	177
7.2 Drug Master Files	177
7.2.1 Types of DMF	177
7.2.2 Who can File DMF?	178
7.2.3 Letter of Authorization (LOA) for DMF	178
7.2.4 Benefits of DMF	180
7.2.5 Importance of Global DMF Submissions	180
7.3 Distribution Records	180
7.3.1 Contents and Format of Distribution Records	180
7.4 Common Technical Dossier/Document (CTD)	181
7.4.1 CTD	181
7.4.2 Electronic Submission of Common Technical Dossier/Document	185
7.5 Asean Common Technical Dossier (ACTD)	187
8. Clinical Trials Studies	189
8.1 Developing Clinical Trial Protocols	189
8.2 Institutional Review Board (IRB)	189
8.2.1 Functions of IRB	190
8.2.2 Formation of IRB	190
8.2.3 Working Procedures	191
8.3 Informed Consent (IC)	192
8.3.1 Process and Procedures of IC	193
8.4 Good Clinical Practice Obligations of Investigators, Sponsors and Monitors	193
8.4.1 Investigators	195
8.4.2 Sponsors	195
8.4.3 Monitors	195
8.5 Pharmacovigilance	196
8.5.1 Objectives of Pharmacovigilance	196
8.5.2 Classification of Adverse Drug Reactions (ADRs)	196
8.6 Clinical Trial Safety Monitoring	197
9. ICH Guidelines	199
9.1 Introduction	199
9.1.1 Objectives	199
9.1.2 History	199
9.1.3 Members	200
9.1.4 Structure	200

9.2 International Council of Harmonization Guidelines	201
9.2.1 ICH Q (Quality) Guidelines	201
9.2.2 ICH S (Safety) Guidelines	214
9.2.3 ICH E (Efficacy) Guidelines	219
9.2.4 ICH M (Multidisciplinary) Guidelines	224

10. US Food and Drug Administration**227**

10.1 Requirements for Product Approval	227
10.1.1 Requirements for API	227
10.1.2 Requirements for Biologics	229
10.2 Requirements for NDA	231
10.2.1 Modern NDA Review Process	231
10.3 Requirements for Abbreviated New Drug Application	232
10.3.1 Modern Generic Drug Submission and GDUFA Implementation	232
10.4 Code of Federal Regulatory/Regulations	233
10.4.1 Recent Developments in CFR Updates	233
10.4.2 Contents of CFR	233
10.4.3 CFR in Pharmaceuticals	234
10.4.4 Future Directions of FDA Regulation	236
Bibliography	237
Index	239